AASraw waxay soo saartaa budada NMN iyo NRC tiro badan!

Erlotinib

Rating: Category:

Budada 'Erlotinib Powder', oo lagu iibiyo magaca magaca 'Tarceva' iyo kuwa kale, waa daawo loo isticmaalo in lagu daaweeyo kansarka sanbabada ee unugyada yar (NSCLC) iyo kansarka ganaca. Gaar ahaan waxaa loo isticmaalaa NSCLC oo leh isbeddelo ku dhaca soo-saaraha koritaanka cuncunka epidermal (EGFR) - ama waa beddelaad exon 19 (del19) ama beddelidda exon 21 (L858R) - taas oo ku faaftay qaybaha kale ee jirka.

Product Description

Astaamaha Aasaasiga ah

Product Name Budada Erlotinib
CAS Number 183321-74-6
Formula kelli C22H23N3O4
Miisaanka Nooca 393.443
Isku mid ahaanshaha CP-358774;

OSI774;

Saldhiga bilaashka ah ee budada 'Erlotinib';

183321-74-6.

Imaanshaha Caddaan cad oo budada ah oo cadceedda cad
Kaydinta iyo Isticmaalka Qalalan, madow iyo 0 - 4 C muddo gaaban (maalmo illaa toddobaadyo) ama -20 C muddo dheer (bilo illaa sannado).

 

Faahfaahinta budada Erlotinib

Budada Erlotinib, oo lagu iibiyo magaca calaamadda Tarceva iyo kuwa kale, waa daawo loo isticmaalo in lagu daaweeyo kansarka sanbabada ee unugyada yar (NSCLC) iyo kansarka ganaca. Gaar ahaan waxaa loo isticmaalaa NSCLC oo leh isbeddello ku dhaca qaybta soo-saaraha kobaca epidermal (EGFR) - ama ka-beddelidda exon 19 (del19) ama beddelidda exon 21 (L858R) - oo ku faafay qaybaha kale ee jirka. Af baa lagu qaataa.

Budada Erlotinib waa quinazoline derivative leh guryaha antineoplastic. Tartan la leh adenosine triphosphate, budada erlotinib ayaa dib ugu laabaneysa xuubka 'intracellular catalytic domain of epidermal growth factor reseptor (EGFR) tyrosine kinase, taasoo markaa dib uga noqonaysa ka hortagga EGFR fosforyaalka iyo joojinta dhacdooyinka wareejinta calaamadaha iyo saamaynta tumorigenic ee la xidhiidha firfircoonaanta EGFR.

Budada Erlotinib waxaa loo ansixiyay in lagu isticmaalo caafimaadka Maraykanka gudihiisa 2004. Waxay ku jirtaa Liiska Daawooyinka Aasaasiga ah ee Ururka Caafimaadka Adduunka, kaas oo ku taxan dawooyinka ugu badbaado badan uguna waxtarka badan ee looga baahan yahay nidaamka caafimaadka.

 

Mashruuca Erlotinib Powder of Action

Budada Erlotinib waa cunsur-ku-soo-kiciyaha kiniiniga koritaanka ee epidermal (EGFR inhibitor). Daroogadu waxay raacdaa Iressa (gefitinib), oo ahayd dawadii ugu horreysay ee noocan ah.

Budada Erlotinib waxay si gaar ah u bartilmaameedsataa soo-saaraha epidermal factor reseptor (EGFR) tyrosine kinase, kaas oo si aad ah loo muujiyo mararka qaarna loo beddelo noocyo kala duwan oo kansar ah. Waxay kuxirantahay qaab beddelid ah adenosine triphosphate (ATP) oo ah goobta qaboojiyaha. Si calaamadda la isugu gudbiyo, laba maaddooliye oo loo yaqaan EGFR ayaa u baahan inay isu yimaadaan si ay u sameeyaan homodimer.

Kuwani waxay markaa u adeegsadaan molecule-ka ATP inay isku-beddelaan-fosforylate-ka mid kasta oo ka mid ah hadhaaga tyrosine, kaas oo soo saara hadhaaga fosfooriyada, iyagoo qoraya borotiinada isku xidha fosfooriyada ee 'EGFR' si loo soo ururiyo dhismayaasha isku-xidhka borotiinka ee u gudbiya calaamadaha cascad-galka nukleus ama hawlgeliya hababka kale ee unugyada kiimikada. Marka budada erlotinib ay ku xidhan tahay EGFR, samaynta hadhaaga fosfoorashin ee EGFR suurtogal maaha oo calaamadaha cascades lama bilaabayo.

Budada Erlotinib sidoo kale waa tyrosine kinase reseptor inhibitor kaas oo loo isticmaalo daaweynta kansarka sanbabada ee unugyada sare ama kansarka. Daaweynta budada Erlotinib waxay la xiriirtaa kor u qaadista ku-meel-gaadhka ah ee heerarka serum aminotransferase inta lagu jiro daweynta iyo xaaladaha dhifka ah ee caafimaad ahaan u muuqda dhaawaca beerka ee ba'an.

 

Codsiga budada Erlotinib 

Budada Erlotinib waa jiilka kowaad ee soo dhaweynta ah ee loo yaqaan 'tyrosine kinase inhibitor' (oo ay weheliso Gefitinib) oo ugu horeyn ku shaqeyneysa qaybta soo-saaraha kobaca epidermal (EGFR), xubin ka tirsan qoyska ErbB. Daroogadu waxay la falgashaa nooca duurjoogta iyo isbeddelka EGFR labadaba. Qoyska ErbB waxay sameyn karaan homodimers ama heterodimers, kuwaas oo inta badan lagu soo daro saameynta hoose iyo cudur-sidaha noocyo badan oo ka mid ah kansarka lagu barto aadanaha. Receptor tyrosine kinase inhibitors (TKI) waxay ka hortageysaa fosforyliyada substrate-keeda ee wadada calaamadaha unugyada. EGFR caadi ahaan waxay door ka ciyaareysaa shaqooyin badan oo gacanta ah, oo ay kujiraan kala duwanaansho, faafitaan, iyo angiogenesis, oo dhammaantood ah astaamaha kansarka.

Isbedelka EGFR ee NSCLC caadi ahaan waa isbeddel firfircoon. Astaamaha bukaan socodka qaarkood ee sameeya jiritaanka isbeddelka EGFR waxay u badan tahay inaysan ku jirin taariikhda sigaar cabista la xaqiijiyay adenocarcinoma iyadoo lagu falanqeynayo falanqaynta taariikheed, qowmiyadda Aasiya, iyo jinsiga dumarka. Isbedelada Secondary ee EGFR caadi ahaan way dhacaan, taas oo qodobkan hoos ku qeexayo.

 

Waxyeelada budada Erlotinib & Digniinta

Dhibaatooyinka soo socda ayaa caan ku ah bukaanada qaata budada 'Erlotinib Powder':

▪ Rash

Arrhea Shuban

Appet Cunto xumo

Daal

Of Neefta oo ku qabata

Ugh Qufac

▪ Lalabbo iyo matag

 

Dhibaatooyinkan soo raaca waa waxyeelooyin aan caadi ahayn oo bukaanjiifka qaata Erlotinib Powder:

Caabuq

So Af xanuun

Ching Cuncun

Skin Maqaar qallalan

Ation Indho cuncun

Ominal Calool xanuun

 

Dhibaatooyinka oo dhan kuma qorna kor. Qaar dhif iyo naadir ah (oo ku dhaca wax ka yar 10% bukaannada) halkan laguma qorin. Si kastaba ha noqotee, waa inaad marwalba ogeysiisaa bixiyahaaga daryeelka caafimaadka haddii aad isku aragto astaamo aan caadi ahayn.

 

Tixraaca

[1] Gao JW, Zhan P, Qiu XY, Jin JJ, Lv TF, Song Y. Erlotinib-ku saleysan labanlaab daaweynta iyo budada erlotinib oo kali ah horey loogu daaweeyay kansarka sanbabada ee aan-yareyn: falanqayn meta ah oo laga soosaaray 24 tijaabooyinka la xakameeyo. Oncotarget. 2017 Meey 31; 8 (42): 73258-73270. doi: 10.18632 / oncotarget.18319. eCollection 2017 Sep 22. Dib u eegis. Caawinaad PMID: 29069867; PubMed Bartamaha PMCID: PMC5641210.

[2] Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T , Yang JC. Budada Gefitinib ama Erlotinib vs Chemotherapy ee EGFR Mutation-kansarka sanbabada ee wanaagsan: Xogta Bukaanka Shakhsiyeed Meta-Falanqaynta Guud ee Badbaadada. J Natl Kansarka Inst. 2017 Jun 1; 109 (6). doi: 10.1093 / jnci / djw279. Dib u eegis. Caawinaad PMID: 28376144.

[3] Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J. Isbarbardhiga gefitinib, budada erlotinib iyo afatinib ee kansarka sanbabada ee unugyada aan yareyn: Falanqeyn meta ah. Kansarka Int J 2017 Jun 15; 140 (12): 2805-2819. doi: 10.1002 / ijc.30691. Epub 2017 Mar 27. Dib u eegis. Caawinaad PMID: 28295308.

[4] "Budada Erlotinib (Tarceva) Isticmaal Muddada Uurka". Daroogada.com. 1 Nofeembar 2019. Dib loo soo celiyey 23 Diseembar 2019.

[5] "Erlotinib budada Monograph ee loogu talagalay Xirfadleyda". Daroogada.com. Raadin 12 November 2019.

[6] "Kiniiniga Tarceva-erlotinib hydrochloride" DailyMed. 12 Diseembar 2018. Dib loo soo celiyey 23 Diseembar 2019.

[7] "Xidhmada Ansixinta Daroogada: Tarceva (Budada Erlotinib) NDA # 021743". Maamulka Cuntada iyo Dawooyinka ee Mareykanka (FDA). 28 Maarso 2005. Waxaa dib loo helay 23 Diseembar 2019.

[8] Raymond E, Faivre S, Armand JP (2000). "Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy". Daroogada. 60 Qalabka 1: 15-23, dood 41-2. doi: 10.2165 / 00003495-200060001-00002. PMID 11129168. S2CID 10555942.